Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Yvonne Greenstreet also recently made the following trade(s):
- On Thursday, July 11th, Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $261.00, for a total value of $1,851,273.00.
- On Tuesday, June 25th, Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99.
Alnylam Pharmaceuticals Stock Up 1.3 %
ALNY opened at $272.05 on Monday. The firm has a market cap of $34.41 billion, a price-to-earnings ratio of -101.51 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $274.93. The business’s 50 day moving average is $208.99 and its two-hundred day moving average is $174.46.
Wall Street Analyst Weigh In
ALNY has been the subject of a number of recent analyst reports. Bank of America raised their price objective on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. BMO Capital Markets reissued an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Finally, Evercore ISI raised their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, June 25th. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $269.32.
Get Our Latest Stock Report on Alnylam Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd grew its holdings in Alnylam Pharmaceuticals by 69.1% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after acquiring an additional 77,307 shares during the period. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC boosted its position in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 4,809 shares in the last quarter. Finally, Westpac Banking Corp boosted its position in Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 566 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
See Also
- Five stocks we like better than Alnylam Pharmaceuticals
- What is the S&P/TSX Index?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What is a Death Cross in Stocks?
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.